Skip to main content
      RT @DrPetryna: #abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNF

      Olga Petryna DrPetryna

      3 years 10 months ago
      #abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr
      RT @RichardPAConway: de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west g

      Richard Conway RichardPAConway

      3 years 10 months ago
      de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo
      RT @uptoTate: Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI
      RT @RichardPAConway: Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concer

      Richard Conway RichardPAConway

      3 years 10 months ago
      Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v
      RT @RichardPAConway: Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving

      Richard Conway RichardPAConway

      3 years 10 months ago
      Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j
      RT @DrPetryna: #abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular s

      Olga Petryna DrPetryna

      3 years 10 months ago
      #abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0
      RT @EBRheum: This might be the greatest honor of my career - thanks for including me @ACRheum!!

      Serious question and I

      Mike Putman EBRheum

      3 years 10 months ago
      This might be the greatest honor of my career - thanks for including me @ACRheum!! Serious question and I’m not sure I want to know the answer Did anyone know the answer? Would be embarrassing 😂🤣😅😳 #ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye
      RT @RichardPAConway: Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (afte

      Richard Conway RichardPAConway

      3 years 10 months ago
      Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw
      RT @KDAO2011: Don't repeat the ENA test!
      Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab),

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Don't repeat the ENA test! Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725
      RT @RHEUMarampa: What's the best tx strategy for SLE-induced severe thrombocytopenia?
      This 10-yr retro study by Dr. Cim

      sheila RHEUMarampa

      3 years 10 months ago
      What's the best tx strategy for SLE-induced severe thrombocytopenia? This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx
      RT @uptoTate: Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37
      RT @RichardPAConway: Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR

      Richard Conway RichardPAConway

      3 years 10 months ago
      Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR and some APLAR countries, but remains hugely imbalanced @rheumnow #ACR22 Abstr#0085 https://t.co/gw4HYaRlIY https://t.co/xueC3cfqyu
      RT @KDAO2011: Should you repeat the dsDNA? SMART-SLE study
      >3400 SLE pts, > 37,582 visits. Pts with fluctuating +

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Should you repeat the dsDNA? SMART-SLE study >3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327
      RT @DrTrishHarkins: ❤️ Beta Blockers in LV-GCA

      📚65 pts LV-GCA

      💊 15(23%) on BB, 50(73%) not

      🩻 new aortic

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      ❤️ Beta Blockers in LV-GCA 📚65 pts LV-GCA 💊 15(23%) on BB, 50(73%) not 🩻 new aortic dilatation on serial imaging in 15 (23%) - ALL in those NOT on beta blocker 💔 More studies needed, but supportive initial data 🔥 @RheumNow #ACR22 Abst#0477
      RT @DrPetryna: #abs0127  #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or &gt;SD

      Olga Petryna DrPetryna

      3 years 10 months ago
      #abs0127  #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or >SD) for pain interference& fatigue domains vs general population. ⬇️ score on PROMIS physical function; 72.9% of subjects had a T-score < 45. https://t.co/5QfwlB98wV
      ×